洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance

前天 17:50
WuXi AppTec TS H1
“Recently, the U.S. Department of Defense included the Company on its 1260H list. This erroneous designation is not supported by facts or law. We have taken legal action to protect the interests of our customers, employees, and shareholders. We believe that the facts will prevail after an objective and fair judicial review of this ongoing litigation.”。 “As technology advancements and science innovations continue to emerge, WuXi AppTec remains steadfast in ‘doing the right thing and doing it right.’ We will relentlessly enable global innovators and realize our vision that ‘every drug can be made and every disease can be treated.’”。 WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients — one collaboration at a time. Learn more at。
<END>
*版权声明:本网站所转载的文章,均来自互联网,旨在传递更多信息。鉴于互联网的开放性和文章创作的复杂性,我们无法保证所转载的所有文章均已获得原作者的明确授权。如果您是原作者或拥有相关权益,请与我们联系,我们将立即删除未经授权的文章。本网站转载文章仅为方便读者查阅和了解相关信息,并不代表我们认同其观点和内容。读者应自行判断和鉴别转载文章的真实性、合法性和有效性。
AI+生命科学全产业链智能数据平台

收藏

发表评论
评论区(0
  • 暂无评论

    摩熵医药企业版
    50亿+条医药数据随时查
    7天免费试用
    摩熵数科开放平台

    全球药物研发中心
    全球研发数据与行业前沿情报

    382,466
    全球在研药物数
    84
    本月临床试验数
    全球批准的新药
    更多
    全球首批
    各国首批
    数据来源:摩熵医药
    更新时间:
    研发动态
    相关报告
    政策法规
    更多信息,请进入全球药物研发中心查看
    原料药
    添加收藏
      新建收藏夹
      取消
      确认